PAX8 (+)/p63 (-) Immunostaining pattern in renal collecting duct carcinoma (CDC): A useful immunoprofile in the differential diagnosis of CDC versus urothelial carcinoma of upper urinary tract

American Journal of Surgical Pathology

Volumn 34, Issue 7, 2010, Pages 965-969

  Albadine, Roula ^a   Schultz, Luciana ^a   Illei, Peter ^a   Ertoy, Dilek ^b   Hicks, Jessica ^a   Sharma, Rajni ^a   Epstein, Jonathan I ^a   Netto, George J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

collecting duct carcinoma; p63; PAX8; urothelial carcinoma

Indexed keywords

PAIRED BOX TRANSCRIPTION FACTOR; PAX8 PROTEIN, HUMAN; TP63 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; TRANSITIONAL CELL CARCINOMA; UROTHELIUM;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CARCINOMA, TRANSITIONAL CELL; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PAIRED BOX TRANSCRIPTION FACTORS; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; UROTHELIUM;

EID: 77954217396     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181dc5e8a     Document Type: Article

References (16)

1. Albadine R, Schultz L, Fajardo DA, et al. PAX8 expression in urothelial neoplasia\an immunohistochemical study of 236 cases. Mod Pathol. 2010;23:174A.
2. Cuckow PM, Nyirady P, Winyard PJ. Normal and abnormal development of the urogenital tract. Prenat Diagn. 2001;21:908-916.
3. Eble JN, Sauter G, Epstein JI, et al. Pathology and genetics of tumours of the urinary system and male genital organs. WHO Classification of Tumours. IARC Press, Lyon, 2004. J.R. Srigley, H. Moch: 2004:33-34.
4. Fedor HL, De Marzo AM. Practical methods for tissue microarray construction. Methods Mol Med. 2005;103:89-101.
5. Gupta R, Paner GP, Amin MB. Neoplasms of the upper urinary tract: a review with focus on urothelial carcinoma of the pelvicalyceal system and aspects related to its diagnosis and reporting. Adv Anat Pathol. 2008;15:127-139.
6. Higgins JP, Kaygusuz G, Wang L, et al. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol. 2007;31:673-680.
7. Janzen N, Zisman A, Pantuck AJ, et al. Minimally invasive ablative approaches in the treatment of renal cell carcinoma. Curr Urol Rep. 2002;3:13-20.
8. Kafe H, Verbavatz JM, Cochand-Priollet B, et al. Collecting duct carcinoma: an entity to be redefined? Virchows Arch. 2004;445: 637-640.
9. Kobayashi N, Matsuzaki O, Shirai S, et al. Collecting duct carcinoma of the kidney: an immunohistochemical evaluation of the use of antibodies for differential diagnosis. Hum Pathol. 2008;39:1350-1359.
10. Lang D, Powell SK, Plummer RS, et al. PAX genes: roles in development, pathophysiology, and cancer. Biochem Pharmacol. 2007;73:1-14.
11. Langner C, Ratschek M, Tsybrovskyy O, et al. P63 immuno-reactivity distinguishes upper urinary tract transitional-cell carcinoma and renal-cell carcinoma even in poorly differentiated tumors. J Histochem Cytochem. 2003;51:1097-1099.
12. Lopez-Beltran A, Scarpelli M, Montironi R, et al. 2004 WHO classification of the renal tumors of the adults. Eur Urol. 2006; 49:798-805.
13. Narlis M, Grote D, Gaitan Y, et al. Pax2 and pax8 regulate branching morphogenesis and nephron differentiation in the developing kidney. J Am Soc Nephrol. 2007;18:1121-1129.
14. Orsola A, Trias I, Raventos CX, et al. Renal collecting (bellini) duct carcinoma displays similar characteristics to upper tract urothelial cell carcinoma. Urology. 2005;65:49-54.
15. Srigley JR, Eble JN. Collecting duct carcinoma of kidney. Semin Diagn Pathol. 1998;15:54-67.
16. Tong GX, Yu WM, Beaubier NT, et al. Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study. Mod Pathol. 2009;22:1218-1227.